Understanding how certain immune cells affect allergic lung inflammation in asthma
Immunoregulatory Role of Conventional Dendritic Cell Type 2 in Allergic Lung Inflammation
This study is looking at a special type of immune cell that might help reduce inflammation in the lungs for people with asthma, and it hopes to find new ways to improve asthma treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11049913 on NIH RePORTER |
What this research studies
This research investigates the role of a specific type of immune cell, known as conventional dendritic cell type 2 (cDC2), in the development and resolution of allergic lung inflammation associated with asthma. The study focuses on a unique subset of these cells that express a specific receptor, CX3CR1, which appears to have anti-inflammatory properties. By analyzing the gene expression patterns and functions of these cells, the research aims to uncover how they contribute to managing allergic responses in the lungs. This could lead to new insights into asthma treatment and management strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with asthma, particularly those experiencing allergic reactions that affect their respiratory health.
Not a fit: Patients with non-allergic asthma or those whose asthma is not influenced by immune cell activity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for asthma by targeting the immune mechanisms involved in allergic lung inflammation.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune cells in asthma, suggesting that this approach could yield valuable insights.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Park, Gye Young — University of Illinois at Chicago
- Study coordinator: Park, Gye Young
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.